It has been suggested that the CBR3-AS1/miR-509-3p/HDAC9 pathway is a valuable target for the therapy of NSCLC since it promotes tumor growth through the development and progression of NSCLC [30]. This evidence concerns the gene HDAC9 and neoplasm.